We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC (NPC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by Jian-jun Li, Sun Yat-sen University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01854203
First Posted: May 15, 2013
Last Update Posted: July 30, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jian-jun Li, Sun Yat-sen University
May 10, 2013
May 15, 2013
July 30, 2013
July 2013
December 2016   (Final data collection date for primary outcome measure)
  • Overall survival [ Time Frame: 3-year ]
    Overall survival is calculated from randomization to death from any cause.
  • Failure-free survival [ Time Frame: 3-year ]
    Failure-free survival is calculated from the date of randomization to the date of the first failure at any site.
  • Locoregional failure-free survival [ Time Frame: 3-year ]
    the latency to the first local failure
  • Distant failure-free survival [ Time Frame: 3-year ]
    The latency to the first remote failure
Same as current
Complete list of historical versions of study NCT01854203 on ClinicalTrials.gov Archive Site
Difference in the complete response rates between the two treatment arms [ Time Frame: 12 weeks after the completion of therapy ]
Same as current
Rates of toxicity [ Time Frame: 3-years ]
Rates of toxicity will also be compared. Rates will be compared by the chi-square test.The Chemotherapy toxicity include thrombocytopenia, leukocytopenia , anemia, granulocytopenia,damage to hepatic function, damage to renal function,constipation, diarrhea,vomiting and rash. The radiotherapy toxicities include mucositis, radiation dermatitis,dysphagia, xerostomia, skin fibrosis, trismus, hearing loss ane cranial neuropathy.
Rates of toxicity [ Time Frame: 3-years ]
Rates of toxicity will also be compared. Rates will be compared by the chi-square test.
 
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma
Concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of treatment-related death and severe acute toxicity. The survival benefit of adding concurrent chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma is unclear. Gemcitabine plus cisplatin chemotherapy combine with radiotherapy was effective and well tolerated by patients with locoregionally advanced NPC.
The purpose of this study is to compare gemcitabine plus cisplatin induction chemotherapy combine intensity-modulated radiotherapy with or without concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to reevaluate the value of concurrent cisplatin when 4 cycles induction chemotherapy (gemcitabine+cisplatin) and IMRT is used.
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Nasopharyngeal Carcinoma
  • Drug: Inductive chemotherapy + concurrent cisplatin and IMRT
    Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2,on day 1) repeated every week for 6 cycles during radiotherapy.
    Other Name: Gemcitabine and cisplatin
  • Drug: Inductive chemotherapy + IMRT
    Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
    Other Name: Gemcitabine and cisplatin
  • Experimental: IInductive chemotherapy + concurrent cisplatin and IMRT
    Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2,on day 1) repeated every weeks for 6 cycles during radiotherapy.
    Intervention: Drug: Inductive chemotherapy + concurrent cisplatin and IMRT
  • Experimental: Inductive chemotherapy + IMRT
    Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
    Intervention: Drug: Inductive chemotherapy + IMRT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
300
December 2016
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO 2005) histologically type).
  • A Karnofsky performance status of at least 80;
  • Tumor staged is according to the 7th American Joint Commission on Cancer edition as Stage III:T1-2N2M0, T3N0-2M0 Stage IVa:T4N0-2M0 Stage IVb:Any T、N3.
  • Adequate marrow: a WBC ≥3.5×109 l-1; a platelet count ≥100×109 l-1; and hemoglobin levels ≥100 g/l.
  • Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.
  • Adequate renal function: a creatinine clearance rate of at least 60 mL/min.
  • Patients must be informed of the investigational nature of this study and give written informed consent.

Exclusion Criteria:

  • WHO Type keratinizing squamous cell carcinoma.
  • Age >65 years or <18 years.
  • Distant metastasis,
  • Treatment with palliative intent.
  • Pregnancy or lactation.
  • a history of previous radiotherapy in the nasopharyngeal region or previous chemotherapy.
  • history of renal disease, unstable cardiac disease requiring treatment.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01854203
ChiECRCT-2013003
Yes
Not Provided
Not Provided
Jian-jun Li, Sun Yat-sen University
Sun Yat-sen University
Not Provided
Study Director: yong Su, M.D. Sun Yat-sen University
Principal Investigator: Janjun Li, M.D. Sun Yat-sen University
Principal Investigator: Lizhi Liu, M.D. Sun Yat-sen University
Sun Yat-sen University
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP